Available Across All 50 US States, Extending Deep Longevity’s AI-Powered Ageing Science Directly to Consumers<\/b> for a Second Growth Curve<\/b><\/p>\n
HONG KONG<\/span>, Sept. 28, 2026<\/span> \/PRNewswire\/ — Regent Pacific Group Limited (“Regent Pacific<\/b>” or the “Company<\/b>“, together with its subsidiaries, the “Group<\/b>“; stock code: 0575.HK), is pleased to announce that Deep Longevity, its AI-powered biological ageing intelligence subsidiary, will launch Accrua\u2122 (“Accrua<\/b>“), its consumer digital health and telehealth platform, in the United States (“US<\/b>“) in October 2026. From launch, Accrua will be available to consumers across all 50 US states offering personalised clinician-guided care anchored to each user’s biological age rather than symptoms alone.<\/p>\n Accrua represents an important step in Deep Longevity’s direct-to-consumer (“D2C”) strategy for the US market, complementing the Group’s existing business-to-business (“B2B”) relationships with clinics, hospitals, laboratories and insurance companies. It marks the first time Deep Longevity’s proprietary and award-winning ageing-clock technology and SenoClock\u00ae platform have been extended directly to consumers, and the Board regards it as a significant new source of future revenue for the Group.<\/p>\n About Accrua<\/u><\/b><\/p>\n Accrua provides medical care online that is simple, direct and led by licensed US clinicians. At the heart of the platform is Deep Longevity’s proprietary, AI-generated BloodAge report, which uses a routine blood test to indicate whether a consumer is a “faster ager” \u2014 someone whose biological age is advancing more quickly than their chronological age.<\/p>\n Following a clinician consultation, Accrua offers doctor-guided access to a range of treatment categories, including medications for weight loss (such as glucagon-like peptide-1 (“GLP-1<\/b>“) therapies), peptides, women’s health (such as hormone replacement therapy) and men’s health (such as testosterone therapies). Each treatment plan is personalised by a licensed clinician and anchored to the user’s BloodAge report \u2014 rather than to self-reported symptoms or a single biomarker \u2014 with BloodAge re-measured quarterly so users and their clinicians can track progress against an objective, science-based measure of biological ageing.<\/p>\n Built around the proposition \u2014 “You know your age. Your blood knows better.” \u2014 Accrua integrates quarterly biological age measurement, clinician-guided treatment and compounded therapies into an integrated longevity care programme backed by peer-reviewed science. Deep Longevity’s BloodAge model was the subject of a peer-reviewed study (Goshen et al., Aging and Disease, 2026) following approximately 2,600 adults over an average of 9.2 years, which found that each additional year of gap between biological and chronological age was associated with a 15% increase in mortality risk. Deep Longevity’s technology was also recently named Runner-Up in the Nestl\u00e9 VITAL Smart Aging Global Challenge, a global innovation competition drawing entries from 150 companies.<\/p>\n A Large<\/u><\/b> and<\/u><\/b> Fast-<\/u><\/b>g<\/u><\/b>rowing Market<\/u><\/b><\/p>\n Accrua is entering a US consumer digital health market in which platforms addressing adjacent categories have achieved substantial revenue. MEDVi, LLC, a US digital telehealth platform focused on GLP-1 weight-loss and related therapies, generated over US$400 million in revenue in 2025, its first full year of operation, and was on track for an approximately US$1.8 billion revenue run-rate in 2026, as reported by The New York Times (2 April 2026) and Forbes (2 April 2026, citing The New York Times). While no assurance can be given that Accrua will achieve comparable results, the Board believes these figures illustrate the scale of consumer demand and the revenue potential of the market Accrua is designed to address.<\/p>\n Capital-<\/u><\/b>e<\/u><\/b>fficient, Scalable Business Model<\/u><\/b><\/p>\n Accrua* has been built on a capital-efficient, scalable model. Clinical delivery will be provided through established US telehealth infrastructure partners and a network of independent, licensed physicians and pharmacy and compounding partners, covering consultations, prescriptions, pharmacy fulfilment, patient intake and billing across all 50 US states \u2014 allowing Deep Longevity to scale nationally from launch without owning clinical infrastructure or carrying drug inventory directly. This approach will minimize upfront capital requirement for expansion while maintaining operational flexibility. Revenue is expected to be largely subscription-based and recurring in nature. The platform operates on HIPAA-compliant infrastructure and will be LegitScript certified ahead of launch. The launch will be supported by targeted digital marketing, initially focused on selected US states, with the aim of optimising customer acquisition before further scaling.<\/p>\n Mr. Jamie Gibson, Executive Director and Chief Executive Officer of the Company, commented:<\/b> “The launch of Accrua is a landmark moment for Deep Longevity and for the Group. For the first time, consumers across the US will be able to access our BloodAge science directly, with personalised care from licensed clinicians. We believe anchoring treatment to biological age \u2014 rather than to symptoms alone \u2014 is a genuinely new proposition in a market that has already demonstrated exceptional consumer demand, and we are excited about the opportunity ahead.”<\/i><\/p>\n *Accrua is a newly launched business, and the revenues to be generated from it, if any, remain uncertain and will depend on a number of factors, including consumer demand, competition and the regulatory environment for digital telehealth in the US.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n About Deep Longevity<\/u><\/b><\/p>\n Deep Longevity is an AI-powered biological ageing intelligence company dedicated to making healthy ageing measurable and actionable. Its proprietary ageing clock technology \u2014 validated through peer-reviewed science and published in leading international journals \u2014 measures biological and cognitive ageing across multiple physiological systems, enabling healthcare and consumer health organisations to integrate personalised ageing intelligence into their products and services. For more information, visit www.deeplongevity.com<\/a>.<\/p>\n About Regent Pacific Group Limited (Stock code: 0575.HK)<\/u><\/b><\/p>\n Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders since its initial public offering in May 1997.<\/p>\n\n\n
\n \n